GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » FCF Yield %

Aprea Therapeutics (Aprea Therapeutics) FCF Yield % : -44.51 (As of Apr. 29, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Aprea Therapeutics's Trailing 12-Month Free Cash Flow is $-12.18 Mil, and Market Cap is $27.36 Mil. Therefore, Aprea Therapeutics's FCF Yield % for today is -44.51%.

The historical rank and industry rank for Aprea Therapeutics's FCF Yield % or its related term are showing as below:

APRE' s FCF Yield % Range Over the Past 10 Years
Min: -134.28   Med: 0   Max: 0
Current: -44.51


APRE's FCF Yield % is ranked worse than
71.98% of 1549 companies
in the Biotechnology industry
Industry Median: -15.5 vs APRE: -44.51

Aprea Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Aprea Therapeutics FCF Yield % Historical Data

The historical data trend for Aprea Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics FCF Yield % Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial -2.77 -40.13 -60.07 -142.29 -69.87

Aprea Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -91.50 -71.92 -109.47 -57.60 -85.18

Competitive Comparison of Aprea Therapeutics's FCF Yield %

For the Biotechnology subindustry, Aprea Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprea Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's FCF Yield % falls into.



Aprea Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Aprea Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-12.271 / 17.562349
=-69.87%

Aprea Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.74 * 4 / 17.562349
=-85.18%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aprea Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Aprea Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprea Therapeutics (Aprea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Executives
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill officer: SrVP/CFO/Prin. Fin &Acctg. Off 4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger director C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey director 27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad officer: President, CEO 535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu director 535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade director, officer: President & CEO MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar officer: SVP, Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel officer: Chief Business Officer 535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen officer: SVP, Chief Scientific Officer 535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Aprea Therapeutics (Aprea Therapeutics) Headlines

From GuruFocus

Aprea Therapeutics Announces Proposed Public Offering of Common Stock

By sperokesalga sperokesalga 02-22-2023

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

By sperokesalga sperokesalga 02-13-2023